{"id":"ven","safety":{"commonSideEffects":[{"rate":"~50","effect":"Neutropenia"},{"rate":"~40","effect":"Thrombocytopenia"},{"rate":"~30","effect":"Anemia"},{"rate":"~35","effect":"Diarrhea"},{"rate":"~25","effect":"Nausea"},{"rate":"~5","effect":"Tumor lysis syndrome"},{"rate":"~30","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL3989686","moleculeType":"Small molecule","molecularWeight":"348.49"},"_dailymed":{"setId":"28c8f404-1dbd-4140-8959-32624d7c7724","title":"VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venetoclax binds directly to BCL-2 and displaces pro-apoptotic proteins (BAX and BAK), allowing them to permeabilize the mitochondrial outer membrane and trigger the intrinsic apoptotic pathway. This mechanism is particularly effective in hematologic malignancies where BCL-2 is overexpressed or where cells are dependent on BCL-2 for survival.","oneSentence":"Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:50:22.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory"},{"name":"Acute myeloid leukemia (AML), newly diagnosed in patients ≥75 years or unfit for intensive chemotherapy"},{"name":"Small lymphocytic lymphoma (SLL), relapsed/refractory"}]},"trialDetails":[{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT06852222","phase":"PHASE3","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-06-04","conditions":"Leukemia, Myeloid, Acute","enrollment":600},{"nctId":"NCT05478512","phase":"PHASE2","title":"Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-07-21","conditions":"High Risk CLL, Chronic Lymphocytic Leukemia","enrollment":78},{"nctId":"NCT04926285","phase":"PHASE1","title":"Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2022-06-21","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":6},{"nctId":"NCT06557421","phase":"PHASE2","title":"De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2026-02-04","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT06456463","phase":"PHASE2","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2025-01-14","conditions":"Acute Myeloid Leukemia","enrollment":83},{"nctId":"NCT05768711","phase":"PHASE2","title":"Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2023-10-04","conditions":"Chronic Myeloid Leukemia","enrollment":44},{"nctId":"NCT07304011","phase":"PHASE2","title":"Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-12-17","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT07243483","phase":"NA","title":"Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2026-01-21","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT06481241","phase":"NA","title":"Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-10","conditions":"Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult","enrollment":77},{"nctId":"NCT06511882","phase":"PHASE2","title":"Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-07","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":33},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT07420790","phase":"","title":"Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2026-02","conditions":"Acute Myeloid Leukemia","enrollment":1941},{"nctId":"NCT06991920","phase":"NA","title":"Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-06-30","conditions":"Adult ALL, MPAL","enrollment":50},{"nctId":"NCT06580106","phase":"","title":"Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-09","conditions":"Leukemia, Myeloid, Acute","enrollment":50},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT06429449","phase":"PHASE1","title":"Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-21","conditions":"Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":30},{"nctId":"NCT05342584","phase":"PHASE1","title":"Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-05-25","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":99},{"nctId":"NCT07318662","phase":"","title":"Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-01-01","conditions":"MDS, CMML","enrollment":224},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT06030089","phase":"NA","title":"Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-02-26","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05168930","phase":"PHASE2","title":"Zanubrutinib and Venetoclax in CLL (ZANU-VEN)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-02-18","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":45},{"nctId":"NCT07264010","phase":"PHASE2, PHASE3","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-12-01","conditions":"Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)","enrollment":87},{"nctId":"NCT05621148","phase":"","title":"REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2023-01-25","conditions":"CLL, Relapsed, CLL, Refractory, Bruton Tyrosine Kinase Inhibitor","enrollment":152},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT05566054","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-03-01","conditions":"Acute Monocytic Leukemia, Newly Diagnosed","enrollment":92},{"nctId":"NCT04666649","phase":"PHASE1","title":"Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-03-10","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":27},{"nctId":"NCT04609826","phase":"PHASE1","title":"A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-26","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":153},{"nctId":"NCT07183878","phase":"NA","title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08-20","conditions":"Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":138},{"nctId":"NCT06918834","phase":"PHASE2","title":"Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-24","conditions":"Myelodysplastic Syndromes","enrollment":236},{"nctId":"NCT04512105","phase":"PHASE1","title":"Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-12-02","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult","enrollment":6},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Adult T-cell Leukemia/Lymphoma","enrollment":27},{"nctId":"NCT06429098","phase":"PHASE2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT07117422","phase":"NA","title":"Venetoclax-Decitabine in Untreated Elderly/Unfit AML","status":"RECRUITING","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2025-01-17","conditions":"AML, Adult","enrollment":39},{"nctId":"NCT07047183","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Yehui Tan","startDate":"2025-07-01","conditions":"Myelodysplastic Neoplasms, Transplantation","enrollment":46},{"nctId":"NCT06158100","phase":"PHASE1","title":"Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","status":"SUSPENDED","sponsor":"Antonio M Jimenez Jimenez","startDate":"2024-12-04","conditions":"Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT06903702","phase":"PHASE2","title":"A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-06-04","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT07052422","phase":"PHASE2, PHASE3","title":"VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-07-15","conditions":"Older Patients, Myeloid Malignancies, Conditioning","enrollment":160},{"nctId":"NCT07007949","phase":"PHASE2","title":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib","enrollment":42},{"nctId":"NCT06390306","phase":"","title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Chronic Myeloid Leukemia","enrollment":30},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT06696183","phase":"PHASE2","title":"Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-04-25","conditions":"AML - Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05401097","phase":"PHASE2","title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","status":"RECRUITING","sponsor":"Alice Mims","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT03295240","phase":"EARLY_PHASE1","title":"The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-20","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":10},{"nctId":"NCT06634394","phase":"PHASE1","title":"APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML","status":"RECRUITING","sponsor":"Aptevo Therapeutics","startDate":"2024-10-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":39},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT06841952","phase":"NA","title":"Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-02-15","conditions":"AML, Adult","enrollment":158},{"nctId":"NCT05870995","phase":"PHASE2","title":"Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-01","conditions":"Refractory Leukemia","enrollment":100},{"nctId":"NCT05881265","phase":"PHASE2","title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-15","conditions":"APL","enrollment":30},{"nctId":"NCT04372433","phase":"PHASE1","title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","status":"COMPLETED","sponsor":"Immune-Onc Therapeutics","startDate":"2020-09-14","conditions":"AML With Monocytic Differentiation, CMML","enrollment":67},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT05996406","phase":"PHASE2","title":"Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-07","conditions":"Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax","enrollment":36},{"nctId":"NCT06763666","phase":"PHASE4","title":"CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-02","conditions":"Relapsed/Refractory AML","enrollment":172},{"nctId":"NCT04476199","phase":"PHASE2","title":"Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2019-12-09","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT06754267","phase":"PHASE2","title":"Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-12","conditions":"Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT06742242","phase":"NA","title":"The Use of Non-ICG-Enhanced Lymphatic Vessels for LVA","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-09","conditions":"Lymphedema","enrollment":106},{"nctId":"NCT05833438","phase":"PHASE2","title":"Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2023-05-17","conditions":"Acute Myeloid Leukemia (AML)","enrollment":45},{"nctId":"NCT05904106","phase":"PHASE2","title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-04-07","conditions":"Acute Myeloid Leukemia","enrollment":146},{"nctId":"NCT06612944","phase":"PHASE2","title":"Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-12","conditions":"Myelodysplastic Syndromes, Adult","enrollment":40},{"nctId":"NCT04763928","phase":"PHASE2","title":"Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-12-03","conditions":"Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT06652685","phase":"PHASE2","title":"Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-10-30","conditions":"Acute Myeloid Leukemia (AML)","enrollment":218},{"nctId":"NCT06287827","phase":"","title":"Treatment of Acute Malnutrition in Outpatient Care Services in Venezuela: a Prospective Cohort Research","status":"COMPLETED","sponsor":"UNICEF - Venezuela","startDate":"2024-02-14","conditions":"Acute Malnutrition in Childhood, Wasting, Child Malnutrition","enrollment":299},{"nctId":"NCT06617663","phase":"NA","title":"Online Therapy Youth, Equivalent to Treatment As Usual?","status":"RECRUITING","sponsor":"GGZ Noord-Holland-Noord","startDate":"2024-07-01","conditions":"Depression, Trauma, Compulsive Disorder","enrollment":172},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT06554626","phase":"PHASE2","title":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-08-15","conditions":"Precursor B-Cell Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT05841771","phase":"PHASE2","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-01-01","conditions":"Hypomethylating Agent, Venetoclax, Myeloid Malignancy","enrollment":78},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT06536010","phase":"NA","title":"Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML","status":"RECRUITING","sponsor":"Yang Xiaotian","startDate":"2021-11-03","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04968015","phase":"PHASE2","title":"Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2022-05-25","conditions":"Acute Myeloid Leukemia","enrollment":134},{"nctId":"NCT06447090","phase":"PHASE2","title":"VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-12","conditions":"Relapse Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06418776","phase":"PHASE3","title":"IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2024-04-01","conditions":"Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia","enrollment":198},{"nctId":"NCT06285136","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Kunming Medical University","startDate":"2024-03-01","conditions":"Acute Myeloid Leukemia, Adult","enrollment":40},{"nctId":"NCT06232694","phase":"NA","title":"Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT05918198","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-02-01","conditions":"Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT06073730","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Kunming Medical University","startDate":"2023-11-01","conditions":"Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia","enrollment":154},{"nctId":"NCT05893472","phase":"PHASE1, PHASE2","title":"A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.","status":"UNKNOWN","sponsor":"ZePing Zhou","startDate":"2023-04-01","conditions":"Acute Myeloid Leukemia, Venetoclax","enrollment":45},{"nctId":"NCT05264883","phase":"PHASE3","title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-01","conditions":"Acute Myeloid Leukemia","enrollment":170},{"nctId":"NCT05543759","phase":"","title":"Simplified Treatment Protocol for Acute Malnutrition in Venezuela","status":"TERMINATED","sponsor":"UNICEF - Venezuela","startDate":"2022-09-05","conditions":"Acute Malnutrition in Childhood, Wasting, Child Malnutrition","enrollment":307},{"nctId":"NCT05823714","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":70},{"nctId":"NCT05809167","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia","enrollment":55},{"nctId":"NCT05805098","phase":"PHASE2, PHASE3","title":"Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05209308","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL","status":"WITHDRAWN","sponsor":"MEI Pharma, Inc.","startDate":"2022-11-22","conditions":"CLL","enrollment":""},{"nctId":"NCT05448599","phase":"PHASE1, PHASE2","title":"A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT05584761","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-01","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1095,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VEN","genericName":"VEN","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis. Used for Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory, Acute myeloid leukemia (AML), newly diagnosed in patients ≥75 years or unfit for intensive chemotherapy, Small lymphocytic lymphoma (SLL), relapsed/refractory.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}